2024
Risk of developing inflammatory arthritis in patients with psoriasis initiating treatment with biologics: A population-based analysis
Strober B, Soliman A, Li C, Patel M, Unigwe I, Gisondi P. Risk of developing inflammatory arthritis in patients with psoriasis initiating treatment with biologics: A population-based analysis. Journal Of The American Academy Of Dermatology 2024, 91: 1143-1149. PMID: 39197499, DOI: 10.1016/j.jaad.2024.06.106.Peer-Reviewed Original ResearchIL-23 inhibitorsDevelopment of inflammatory arthritisIL-23IL-17Inflammatory arthritisPsO patientsTNF inhibitorsMultivariate Cox proportional hazards modelDiagnosis of inflammatory arthritisPatients initiate treatmentCox proportional hazards modelsData Mart DatabaseAdjusted hazard ratiosProportional hazards modelIL-12/23Hazard ratioLow riskPatientsProtopathic biasBaseline diagnosisIncidence rateHazards modelArthritisTNFEffect of biological treatment
2017
Current biologic therapies (including IL-17) and monitoring guidelines
Strober B, Wald J. Current biologic therapies (including IL-17) and monitoring guidelines. 2017, 233-240. DOI: 10.1201/9781315119298-23.Peer-Reviewed Original ResearchTuberculin skin testLatent tuberculosisBiologic therapyQuantiFERON-TB Gold testPhase 3 clinical trialsCurrent biologic therapiesInitiation of treatmentSeverity Index scoreInterferon-gamma releaseEfficacy of treatmentHuman monoclonal antibodyMembrane-bound TNFPsoriasis AreaAtypical presentationGamma releaseSkin testThorough historyClinical trialsGold testIndex scoreControl populationMonoclonal antibodiesTNFAdverse effectsTuberculosis